Scarlet lands €12 million DARPA grant for smart red blood cells
What's the deal? UK biotech Scarlet TherapeuticsDealroom has a profile for this one. Try Dealroom → will lead a consortium developing red blood cells that sense physiological changes and respond to them, backed by a grant worth up to €12 million ($14 million) from the US Defense Advanced Research Projects Agency (DARPA)Dealroom has a profile for this one. Try Dealroom →. The company will coordinate work with the University of BristolDealroom has a profile for this one. Try Dealroom →, where its technology originated; Northwestern UniversityDealroom has a profile for this one. Try Dealroom →; and UK cell-manufacturing firm Unicorn BiotechnologiesDealroom has a profile for this one. Try Dealroom →.
What's the endgame? The project pushes Scarlet's technology beyond using engineered red blood cells as passive carriers of therapeutic proteins. The goal is to equip them with biological circuits that sense a signal, make a decision, and switch a response on or off.
Why now? The grant supports DARPADealroom has a profile for this one. Try Dealroom →'s Smart-RBC program, which aims to boost physiological resilience and temporarily improve the natural capabilities of military personnel in extreme environments. Its materials describe the objective as optimising warfighter physiology using red blood cells equipped with "sense, decide, and act" circuits.
Scarlet's work will focus on cells that respond to conditions such as hypoxia — low oxygen — by activating systems that remove toxic metabolites from the bloodstream, chief executive officer Alistair Irvine told European Biotechnology. That maps onto Scarlet's existing therapeutic work, which includes clearing ammonia or oxalate from patients with hyperammonemia or hyperoxaluria.
What could go wrong? The technology carries an obvious dual-use dimension. Asked whether it could eventually improve tolerance to hypoxia, heat, or fatigue in healthy people, Irvine said "the potential applications are broad," but added that Scarlet remains focused on developing treatments for patients.
Scarlet and its partners retain commercial rights, and intellectual property generated during the project will belong to the company or its consortium partners; details of the US government's associated rights are confidential. Irvine said "most of, if not all" of the technology should transfer into Scarlet's therapeutic programs.
The signal: At €12 million, the grant sits in the top 1% of all health-sector grant rounds recorded in the UK. It marks a growing overlap between defence funding and frontline synthetic biology, where military resilience goals and patient therapeutics increasingly draw on the same engineered building blocks.
Read more: european-biotechnology.com
Image credit: Scarlet Therapeutics
